HER2 Circulating Tumor Cells in Gastric Cancer
NCT01299688 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 135
Last updated 2018-01-17
Summary
The investigators propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer.
Conditions
Sponsors & Collaborators
-
Samsung Medical Center
lead OTHER
Principal Investigators
-
Won Ki Kang, MD · Samsung Medical Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-03-31
- Primary Completion
- 2013-03-11
- Completion
- 2013-03-11
Countries
- South Korea
Study Locations
More Related Trials
-
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
NCT04309578 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
NCT01450696 ·Status: TERMINATED ·Phase: PHASE3
-
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC
NCT04168931 ·Status: TERMINATED ·Phase: PHASE2
-
Trastuzumab Based Therapy in HER2 Positive AGC
NCT03024450 ·Status: COMPLETED
-
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
NCT01260194 ·Status: TERMINATED ·Phase: PHASE4
-
PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer
NCT01152853 ·Status: COMPLETED ·Phase: PHASE2
-
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
NCT02004769 ·Status: COMPLETED ·Phase: PHASE2
-
Her 2 Testing in Indian Patients With Gastric Cancer
NCT01814345 ·Status: TERMINATED
-
Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy
NCT05640830 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
NCT03766607 ·Status: WITHDRAWN ·Phase: PHASE2
-
An Observational Study of Herceptin (Trastuzumab) in Patients With HER2-positive Advanced Gastric Cancer
NCT01220934 ·Status: COMPLETED
-
S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer
NCT00343668 ·Status: UNKNOWN ·Phase: PHASE2
-
Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy (ONCO-RD 010 CRT)
NCT02686424 ·Status: SUSPENDED
-
Multicenter Phase III Trial of Laparoscopic Sentinel Node Biopsy
NCT01804998 ·Status: COMPLETED ·Phase: NA
-
Herzuma-capecitabine/Cisplatin for Gastric Cancer
NCT03588533 ·Status: UNKNOWN ·Phase: PHASE2
-
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
NCT01396707 ·Status: COMPLETED ·Phase: PHASE2
-
Antiangiogenic Factors in Gastric Cancer
NCT00735566 ·Status: COMPLETED
-
Predicting Biomarker of Gastric Cancer Chemotherapy Response
NCT03253107 ·Status: RECRUITING
-
A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
NCT02005484 ·Status: TERMINATED ·Phase: PHASE2
-
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
NCT03185988 ·Status: UNKNOWN ·Phase: PHASE2
-
Quality Control Study of Laparoscopic Sentinel Node Biopsy in Early Gastric Cancer
NCT01544413 ·Status: COMPLETED ·Phase: NA
-
Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer
NCT02805829 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201
NCT07333820 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Study of Afuresertib Combined With Paclitaxel in Gastric Cancer
NCT02240212 ·Status: COMPLETED ·Phase: PHASE1
-
Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer
NCT05348161 ·Status: UNKNOWN ·Phase: NA